ravulizumab-cwvz

ravulizumab-cwvz (ULTOMIRIS) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

ULTOMIRIS is a marketed brand name for ravulizumab-cwvz. Check FDA Drugs@FDA for the current US label holder and prescribing information.

ravulizumab-cwvz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.